Please assess the completion status of the following clinical trial:

Trial Title: Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically, cytologically, or serologically\* confirmed hepatocellular carcinoma meeting the following criteria:~  * 1-4 lesions~ * Involvement of 1 or both liver lobes NOTE: \*Alpha-fetoprotein (AFP) \> 500 mcg/L in high-risk patients~* Measurable disease by CT scan or MRI~  * Disease does not exceed 50% of the liver parenchyma~ * At least 1 lesion ≥ 3 cm in longest diameter~* Tumor burden involves \< 50% of the liver~* Refused surgery OR unresectable disease due to any of the following:~  * Multifocality~ * Advanced cirrhosis~ * Comorbid illness~* Candidate for chemoembolization~* No fibrolamellar histology~* No ascites~* No known brain metastases~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy ≥ 12 weeks~* WBC ≥ 3,000/mm³~* ANC ≥ 1,500/mm³~* Hemoglobin ≥ 8.5 g/dL (transfusion allowed)~* Platelet count ≥ 100,000/mm³~* Bilirubin ≤ 2 mg/dL~* AST ≤ 5 times upper limit of normal (ULN)~* INR \< 1.5~* Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 30 mL/min~* No bleeding diathesis or coagulopathy~* No active congestive heart failure~* No uncontrolled angina~* No myocardial infarction within the past 12 months~* No cardiac arrhythmia~* Ejection fraction ≥ 45% (in patients with known coronary artery disease and in patients \> 50 years of age)~* Child-Pugh class A or B cirrhosis~* No impedance of hepatopedal blood flow (portal vein thrombosis)~* No thrombosis of the main portal vein~* No encephalopathy~* No biliary obstruction~* No variceal bleed within the past 6 months~* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib malate~* No absolute contraindication to doxorubicin, iodinated contrast material, microfibrillar collage hemostat, or dexamethasone~* No other concurrent uncontrolled illness including, but not limited to, any of the following:~  * Ongoing or active infection~ * Psychiatric illness or social situation that would limit compliance with study requirements~* No other active malignancies within the past year except nonmelanoma skin cancer or carcinoma in situ~* No significant traumatic injury within the past 4 weeks~* No QTc prolongation (i.e., QTc interval ≥ 500 msec) or other significant ECG abnormalities~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 6 months after the completion of study treatment~PRIOR CONCURRENT THERAPY:~* Recovered from prior therapy~* Prior liver-directed therapy, such as chemoembolization, radiofrequency ablation, cryoablation, or ethanol injection allowed if the following criteria are met:~  * Treated lesion remains inactive by CT scan or MRI and new lesion being embolized is distinct from the previously treated lesion~ * Radiographic progression of previously treated lesion requiring re-embolization~* Prior liver resection allowed~* Prior immunotherapy allowed~* No prior antiangiogenesis therapy~* No prior liver transplantation~  * Patients awaiting a cadaveric or orthotopic liver transplantation are eligible provided they have end-stage liver disease with a priority score of \< 20 points~* More than 4 weeks since prior radiotherapy or chemotherapy (6 weeks for nitrosoureas or mitomycin C)~* More than 4 weeks since prior major surgery or open biopsy~* At least 1 week since prior fine needle biopsy~* No concurrent immunotherapy~* No concurrent radiotherapy~* No concurrent combination antiretroviral therapy for HIV-positive patients~* No concurrent therapeutic doses of coumarin-derivative anticoagulants (e.g., warfarin)~  * Doses of ≤ 1 mg/day are allowed for prophylaxis of thrombosis as long as INR ≤ 1.5~ * Both full dose and prophylactic dose low molecular weight heparin allowed as long as PT INR ≤ 1.5~* No anticipated major surgery during and for 3 months after completion of study treatment~* No other concurrent investigational agents~* No other concurrent anticancer therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Sunitinib (Type: EXPERIMENTAL): oral sunitinib malate once daily on days 1-7 and 15-35 in course 1 and on days 1-28 in all subsequent courses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues